RE:RE:Short term cash is a problem unless they sell PRV ASAPLOL, they made a deal to sell two collection facilities, Ryplazim (their only revenue) and sold 30% of the voucher for $22M.
LMNL get 70% of the voucher when sold. Should be about $70M coming from the voucher. Thats a total of $92M.
Had LMNL just sat on their hands and not made this dumb deal two weeks before FDA approval, they would have had $100M, kept the two collection facilities and kept Ryplazim and its revenue stream. This is the deal StupsNewcamo thinks is good. Nothing left.
Newcamo wrote: they just made a deal for 100M$ dude, are u ok stockbaboon?:)))
June 11, 2021 - 12:05 PM
47 Reads
Post# 33372560
money not a problem anymore
with this FDA ok, we can sell that riplazym voucher...market price is between 80M$-120M$ u.s., so lets say 100M$ u.s., we get 70%.... 70M$ u.s. + 17M$ u.s. we cashed already, around 100M$ can$ , lmnl will be able to execute big time and do more deals like this (sell or partner), we gat some in the oven already. Doyour dd. Dont listen to the clown$ operating on this board. They are here for $$$... accumulation time....